Published online before print November 3, 2003
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Article |
,
,
,
*Department of Gastroenterology and Liver Unit, Institut de Malalties Digestives, Hospital Clínic, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Spain; Department of Pathology, School of Clinical and Laboratory Sciences, University of Newcastle-upon-Tyne, Royal Victoria Infirmary, United Kingdom; Department of Pathology, Hospital Mutua of Terrassa, Barcelona, Spain; ¶Histopathology Unit, Cancer Research UK, London Research Institute, United Kingdom; and ||Novo Nordisk A/S, Bagsvaerd, Denmark
@ To whom correspondence should be addressed. E-mail: panes{at}medicina.ub.es.
There is evidence for a beneficial effect of trefoil peptides in animal models of gastric damage and intestinal inflammation, but the optimal treatment strategy and the mechanistic basis have not been explored thoroughly. It has been suggested that these proteins may modulate the inflammatory response. The aims of this study were to compare the protective and curative value of systemic and topical trefoil factor family (TFF)2 administration in dextran sulfate sodium-induced experimental colitis and to investigate the relationship between the therapeutic effects of TFF2 and modulation of leukocyte recruitment and expression of cell adhesion molecules. Clinical and morphologic severity of colitis was evaluated at the end of the study (Day 10). Leukocyte-endothelial cell interactions were determined in colonic venules by fluorescence intravital microscopy. The expression of cell adhesion molecules vascular cell adhesion molecule 1 (VCAM-1) and mucosal addressin cell adhesion molecule 1 (MAdCAM-1) was measured by the dual radiolabeled monoclonal antibody technique. Pretreatment with TFF2 by subcutaneous or intracolonic (ic) route ameliorated the clinical course of colitis, and the luminal route had a significantly superior effect. This beneficial effect was correlated with significant reductions in endothelial VCAM-1 but not MAdCAM-1 expression and leukocyte adhesion to intestinal venules, which returned to levels similar to those of controls. In established colitis, ic TFF2 treatment did not modify the severity of colonic lesions. In conclusion, TFF2 is useful in the treatment of colitis, and topical administration is superior to the systemic route. Reduction in adhesion molecule expression and leukocyte recruitment into the inflamed intestine contribute to the beneficial effect of this treatment.
Key Words: intravital microscopy • cell adhesion molecule • MAdCAM-1
This article has been cited by other articles:
 |
|
 |
|
  Z. Dubeykovskaya, A. Dubeykovskiy, J. Solal-Cohen, and T. C. Wang Secreted Trefoil Factor 2 Activates the CXCR4 Receptor in Epithelial and Lymphocytic Cancer Cell Lines J. Biol. Chem., February 6, 2009; 284(6): 3650 - 3662. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Tu, A. L. Chi, S. Lim, G. Cui, Z. Dubeykovskaya, W. Ai, J. V. Fleming, S. Takaishi, and T. C. Wang Gastrin regulates the TFF2 promoter through gastrin-responsive cis-acting elements and multiple signaling pathways Am J Physiol Gastrointest Liver Physiol, June 1, 2007; 292(6): G1726 - G1737. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. A. Kurt-Jones, L. Cao, F. Sandor, A. B. Rogers, M. T. Whary, P. R. Nambiar, A. Cerny, G. Bowen, J. Yan, S. Takaishi, et al. Trefoil Family Factor 2 Is Expressed in Murine Gastric and Immune Cells and Controls both Gastrointestinal Inflammation and Systemic Immune Responses Infect. Immun., January 1, 2007; 75(1): 471 - 480. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. E. Barrett A new twist on trefoils. Focus on "TFF3 modulates NF-{kappa}B and a novel regulatory molecule of NF-{kappa}B in intestinal epithelial cells via a mechanism distinct from TNF-{alpha}" Am J Physiol Cell Physiol, November 1, 2005; 289(5): C1069 - C1071. [Full Text] [PDF]
|
|
